Clinical Trials Directory

Trials / Terminated

TerminatedNCT00362765

Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study

Assessment of Insulin Sensitivity in Type 2 Diabetics Treated With Metformin, Fenofibrate and Their Combination.

Status
Terminated
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
8 (actual)
Sponsor
Solvay Pharmaceuticals · Industry
Sex
All
Age
40 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Double-blind, randomized placebo-controlled study in type 2 diabetes and dyslipidemic patients.Patients will be randomized to one of four treatment arms for 16 weeks: placebo, fenofibrate, metformin, or metformin and fenofibrate combination.

Conditions

Interventions

TypeNameDescription
DRUGFenofibrate160 mg
DRUGMetformin2000 mg
DRUGPlaceboPlacebo

Timeline

Start date
2006-10-01
Completion
2007-07-01
First posted
2006-08-10
Last updated
2008-08-13

Locations

3 sites across 3 countries: Finland, Ireland, Italy

Source: ClinicalTrials.gov record NCT00362765. Inclusion in this directory is not an endorsement.

Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study (NCT00362765) · Clinical Trials Directory